The Food and Drug Administration accepted Bionovo Inc.'s protocol for an early-stage clinical trial of BZL101, a drug for metastatic breast cancer.
Emeryville-based Bionovo (OTCBB BNVI) said Tuesday that the Phase I/II trial will be run at 10 centers in the United States. The company will enroll the first patients in the trial next year in the first quarter. Dr. Debu Tripathy of the University of Texas Southwestern Medical Center in Dallas will be the principal investigator in the trial.
Tripathy worked previously on Herceptin trials for Genentech Inc. (NYSE DNA)
Emeryville-based Bionovo (OTCBB BNVI) said Tuesday that the Phase I/II trial will be run at 10 centers in the United States. The company will enroll the first patients in the trial next year in the first quarter. Dr. Debu Tripathy of the University of Texas Southwestern Medical Center in Dallas will be the principal investigator in the trial.
Tripathy worked previously on Herceptin trials for Genentech Inc. (NYSE DNA)
posted by doublezero at
1:41 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home